This paper is the first to explore the impact of culture on the acceptability of workplace bullying and to do so across a wide range of countries. Physically intimidating bullying is less acceptable than work related bullying both within groups of similar cultures and globally. Cultures with high performance orientation find bullying to be more acceptable while those with high future orientation find bullying to be less acceptable. A high humane orientation is associated with finding work related bullying to be less acceptable. Confucian Asia finds work-related bullying to be more acceptable than the Anglo, Latin America, and Sub-Saharan Africa country clusters and finds physically intimidating bullying to be more acceptable than the Anglo and Latin America country clusters. The differences in the acceptability of bullying with respect to these cultures are partially explained in terms of cultural dimensions.

It is unclear whether the common belief that experience benefits new product development performance is driven by decision-makers allocating more attention to success experience or more attention to failure experience. This paper differentiates between the two aforementioned types of experience in order to explore their separate effects on new product development performance. We find that only late-stage failure experience improves performance, that success experience is more beneficial than late-stage failure experience and that, while others' related failure experience increases the likelihood of failure, others' related success experience decreases it. We conducted our research in the context of drug development in the biotech industry and obtained our data from Pharma Projects.

One conclusion from the knowledge-based view is that firms develop knowledge from experience. This paper examines the conditions under which firms' R&D experiences might have stronger or weaker effects on innovation capabilities. We posit that any potential benefit depends on the nature of this experience. In particular, we look at how technological area experience and experience diversity affects innovation capabilities. We further propose that, in order to leverage their experience, firms need to consider how the interactions of technological area experience and experience diversity affect performance. To test this model, we draw on a data set of 3034 drug development projects undertaken by 30 large pharmaceutical companies between

No abstract

No abstract